Tags » Chronic Lymphocytic Leukemia

FDA Expands Approved Use of Imbruvica for Chronic Lymphocytic Leukemia

The U.S. Food and Drug Administration today expanded the approved use ofImbruvica (ibrutinib) to treat patients with chronic lymphocytic leukemia (CLL) who carry a deletion in chromosome 17 (17p deletion), which is associated with poor responses to standard treatment for CLL. 567 more words

NEWS

FDA Expands Ibrutinib Approval for Patients with CLL

Earlier today the US FDA announced approval for the expanded use of ibrutinib (Imbruvica) to treat patients with chronic lymphocytic leukemia (CLL), who carry a deletion in chromosome 17 (17p deletion). 106 more words

Lymphoma News

Day +11: I’m Brave? I’m a hero?

I’ve read it from many of my Facebook friends. “You are incredibly brave.” “You are a hero.”

The thing is, I don’t feel like a hero, super or otherwise. 445 more words

Day +10: We Have Liftoff!

I know, I haven’t written anything lately, but that doesn’t mean I haven’t been busy. This transplant business is heavy work! (Well it is, but not like bailing hay heavy.) The truth of the matter is that I haven’t had the energy to even think about writing unless I absolutely have to. 507 more words

My Journey

I would like to tell you a story I have read many times. It is an old story, written very long ago, a story that everyone should know. 947 more words

CLL

FDA Breakthrough Therapy Designation: 5th Approval Is For Gilead Sciences

The FDA announces on July 23rd, that Gilead Sciences’ drug, Zydelig (Idelalisib), receives 3 approvals for blood cancers.

The 1st FDA approval is the “traditional approval” of Gilead Sciences’ FDA Breakthrough Therapy (BTD) Designated product, Zydelig, for relapsed Chronic Lymphocytic Leukemia (CLL). 310 more words

Orphan Drug Development

Zydelig Approved by FDA for Patients with CLL, FL, & SLL

Earlier this afternoon the FDA announced the approval of Zydelig (idelalisib) for patients with relapsed chronic lymphocytic leukemia (CLL). Accelerated approval was also granted for the use of  Zydelig in patients with relapsed follicular B-cell non-Hodgkin lymphoma (FL) and relapsed small lymphocytic lymphoma (SLL). 239 more words

Lymphoma News